Development of polymer film dosage forms of lidocaine for buccal administration

Okamoto, Hirokazu; Taguchi, Hayao; Iida, Kotaro; Danjo, Kazumi

doi:10.1016/s0168-3659(01)00509-0

Cited by 63 publications

(34 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 A portion of 6.25 cm 2 (2.5 cm Â 2.5 cm) of film was used. A side of the film was attached with double adhesive tape on the inert support and, after 2 min, the vessel was filled with pH 6.75 simulated salivary fluid maintained at 378C and stirred at 50 rpm.…”

Section: In Vitro Release Studies and Kinetic Analysismentioning

confidence: 99%

Development of Mucoadhesive Films for Buccal Administration of Flufenamic Acid: Effect of Cyclodextrin Complexation

Mura

Corti

Cirri

et al. 2010

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: In Vitro Release Studies and Kinetic Analysismentioning

confidence: 99%

Development of Mucoadhesive Films for Buccal Administration of Flufenamic Acid: Effect of Cyclodextrin Complexation

Mura

Corti

Cirri

et al. 2010

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…A dissolution apparatus was modified from the original construction of Okamoto et al 8) Briefly, a 10-ml beaker was used as the receptor compartment and a piece of sample film (3-cm diameter) attached to the inner wall of the beaker using double-sided tape, to produce the donor side. An 0.1 M phosphate buffer (PB) (pH 7.0) was then added to the beaker, which was maintained at 37°C and stirred at a constant speed using a magnetic bead.…”

Section: Film Preparationmentioning

confidence: 99%

Oral Candidiasis Deteriorated by Local Application of a Glucocorticoid-Containing Film in a Mouse Model

Yanagi

Hisajima

Ishibashi

et al. 2008

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

The anti-inflammatory agent glucocorticoid is one of the most effective and widely-used drugs for various kinds of inflammatory diseases. However, it has serious side effects, including suppression of host defense mechanisms against microbial infections. Therefore, more efficient delivery methods of glucocorticoids are required for various types of inflammatory diseases. For clinical use films containing glucocorticoids have been developed for oral inflammatory diseases, including mucosal lesions in the oral cavity. Very recently we succeeded in preparing mucoadhesive hydroxypropyl cellulose (HPC)-film containing more than 100 mg/cm 2 of beclomethasone dipropionate (BDP). Before conducting clinical research on this film, the effects of application of this film on oral infection were examined in an animal model, since it is well known that glucocorticoids predispose to oral or pharyngeal Candida infection. [1][2][3][4][5][6] In our previous papers, a murine oral candidiasis model 6) or an esopharynxial model 7) were used, allowing the examination of the effects of topical application of mucoadhesive films.In the present study, we examined the effects of BDP-and neutrophil-Candida interactions in vitro, as well as the level to which oral application of BDP-containing HPC-film predisposes towards oral candidiasis in this murine model. MATERIALS AND METHODS Film PreparationThe film was composed of one layer of HPC (150-400 cP; Wako Pure Chemical Industries, Ltd., Osaka, Japan) as the base component. To prepare BDP-containing film, BDP (Wako) was first dissolved in ethanol, HPC added, and then ethanol added to give a final volume of 30 ml per 0.9 g HPC. A 10-ml aliquot of this solution was cast using a graduated pipette at a rate of 10 ml/4 min into a flat round Teflon dish of diameter 75 mm and then dried on a clean bench overnight. These dried films were then cut into circles of diameter 30 mm for the release study or into rectangles of 0.6 cmϫ0.5 cm for the oral candidiasis study in mice.Release of BDP from the Film Measurement of BDPrelease from the BDP-containing films was performed as follows. A dissolution apparatus was modified from the original construction of Okamoto et al.8) Briefly, a 10-ml beaker was used as the receptor compartment and a piece of sample film (3-cm diameter) attached to the inner wall of the beaker using double-sided tape, to produce the donor side. An 0.1 M phosphate buffer (PB) (pH 7.0) was then added to the beaker, which was maintained at 37°C and stirred at a constant speed using a magnetic bead. Aliquots (100 ml each) were withdrawn at preset times (1, 2, 3, 4, 5, and 30 min), and then the amount of BDP released estimated using an HPLC system (Shimadzu Co., Ltd., Kyoto, Japan) equipped with a UV detector (wavelengthϭ254 nm). To maintain a constant volume and sink conditions in the experiment, the removed solution was replaced each time with 100 ml of 0.1 M PB prewarmed to 37°C. The cumulative amount of drug release per 1 cm 2 of BDP film was then calculated. Each experiment was perf...

show abstract

“…Local administration of these drugs, as a buccal dosage, can provide an effective route for treating dental pain (12). Over the last decade, extensive progress has been made in the development of buccal dosage forms (1).…”

mentioning

confidence: 99%

Development of an ANN optimized mucoadhesive buccal tablet containing flurbiprofen and lidocaine for dental pain

et al. 2016

View full text Add to dashboard Cite

Development of an ANN optimized mucoadhesive buccal tablet containing flurbiprofen and lidocaine for dental painA novel mucoadhesive buccal tablet containing flurbiprofen (FLB) and lidocaine HCl (LID) was prepared to relieve dental pain. Tablet formulations (F1-F9) were prepared using variable quantities of mucoadhesive agents, hydroxypropyl methyl cellulose (HPMC) and sodium alginate (SA). The formulations were evaluated for their physicochemical properties, mucoadhesive strength and mucoadhesion time, swellability index and in vitro release of active agents.Release of both drugs depended on the relative ratio of HPMC:SA. However, mucoadhesive strength and mucoadhesion time were better in formulations, containing higher proportions of HPMC compared to SA. An artificial neural network (ANN) approach was applied to optimise formulations based on known effective parameters (i.e., mucoadhesive strength, mucoadhesion time and drug release), which proved valuable. This study indicates that an effective buccal tablet formulation of flurbiprofen and lidocaine can be prepared via an optimized ANN approach.Keywords: dental pain, mucoadhesion time, mucoadhesive strength, buccal tablet, artificial neural network Dental pathologies/disorders are usually associated with inflammation and moderate to severe pain (1). These are managed using analgesics alone or in combination with a variety of other drugs, e.g., antibiotics, local anaesthetics, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors (2, 3). Among analgesics, opioids and NSAIDs are commonly used to control acute dental pain. Opioids work by blocking nociceptors and are considered superior to NSAIDs. However, due to adverse drug reactions and psychological adherence, opioids require professional supervision, which restricts their use (4). NSAIDs, at higher doses, are usually considered the drugs of choice in dental pain (5). Among NSAIDs, flurbiprofen (FLB), a propionic acid derivative, is a drug used to treat acute pain associated with dental pathology (6, 7). For FLB, the recommended maximum daily dose is 300 mg; however, a single dose of 100 mg can be effective in treating dental pain (8).

show abstract

Development of polymer film dosage forms of lidocaine for buccal administration

Cited by 63 publications

References 14 publications

Development of Mucoadhesive Films for Buccal Administration of Flufenamic Acid: Effect of Cyclodextrin Complexation

Development of Mucoadhesive Films for Buccal Administration of Flufenamic Acid: Effect of Cyclodextrin Complexation

Oral Candidiasis Deteriorated by Local Application of a Glucocorticoid-Containing Film in a Mouse Model

Development of an ANN optimized mucoadhesive buccal tablet containing flurbiprofen and lidocaine for dental pain

Contact Info

Product

Resources

About